Showing results (281-290 of 338) with videos related to

Sort By:
Pageof 34
Cell Death and Differentiation|January 12, 2022
Externalized phosphatidylinositides on apoptotic cells are eat-me signals recognized by CD14Ok-Hee Kim, Geun-Hyung Kang, June Hur, et al.
Journal of Hepatology|April 30, 2023
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastographyJia-Xu Liang, Javier Ampuero, Hao Niu, et al.
American Journal of Cancer Research|September 10, 2019
Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutationsJunyoung Choi, Shinkyo Yoon, Deokhoon Kim, et al.
American Journal of Cancer Research|October 12, 2020
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancerJunyoung Choi, Hee Jin Lee, Shinkyo Yoon, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2026
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trialFabrice Barlesi, Jin Seok Ahn, Benjamin J Solomon, et al.
The Lancet. Oncology|July 11, 2015
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialJean-Charles Soria, Yi-Long Wu, Kazuhiko Nakagawa, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Increased intracellular Ca2+ concentrations prevent membrane localization of PH domains through the formation of Ca2+-phosphoinositidesJin Ku Kang, Ok-Hee Kim, June Hur, et al.
Annals of Hematology|December 22, 2009
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) studySung Yong Oh, Won Seog Kim, Jin Seok Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 StudyMichael Boyer, Mehmet A N Şendur, Delvys Rodríguez-Abreu, et al.
The Lancet. Oncology|May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyByoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.
Pageof 34